A detailed history of Tower Research Capital LLC (Trc) transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 8,257 shares of LYEL stock, worth $9,082. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,257
Previous 24,861 66.79%
Holding current value
$9,082
Previous $36,000 69.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.13 - $1.88 $18,762 - $31,215
-16,604 Reduced 66.79%
8,257 $11,000
Q2 2024

Aug 13, 2024

BUY
$1.3 - $3.01 $27,101 - $62,749
20,847 Added 519.36%
24,861 $36,000
Q1 2024

May 15, 2024

SELL
$1.71 - $3.07 $49,636 - $89,112
-29,027 Reduced 87.85%
4,014 $8,000
Q4 2023

Feb 13, 2024

BUY
$1.39 - $2.35 $5,361 - $9,063
3,857 Added 13.22%
33,041 $64,000
Q3 2023

Nov 14, 2023

BUY
$1.45 - $3.35 $36,993 - $85,468
25,513 Added 694.99%
29,184 $42,000
Q2 2023

Aug 14, 2023

SELL
$1.89 - $3.86 $13,260 - $27,081
-7,016 Reduced 65.65%
3,671 $11,000
Q1 2023

May 09, 2023

BUY
$1.97 - $3.58 $15,070 - $27,387
7,650 Added 251.89%
10,687 $25,000
Q4 2022

Feb 10, 2023

SELL
$2.78 - $8.09 $15,315 - $44,567
-5,509 Reduced 64.46%
3,037 $10,000
Q3 2022

Nov 10, 2022

BUY
$5.54 - $8.27 $3,473 - $5,185
627 Added 7.92%
8,546 $63,000
Q2 2022

Aug 15, 2022

SELL
$3.68 - $6.8 $2,745 - $5,072
-746 Reduced 8.61%
7,919 $51,000
Q1 2022

May 12, 2022

SELL
$5.05 - $7.7 $888 - $1,355
-176 Reduced 1.99%
8,665 $44,000
Q4 2021

Feb 14, 2022

BUY
$7.13 - $15.19 $45,346 - $96,608
6,360 Added 256.35%
8,841 $68,000
Q3 2021

Nov 15, 2021

BUY
$11.0 - $17.95 $27,291 - $44,533
2,481 New
2,481 $37,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.